Table 4.
The characteristics of ADRs aspect by the severity.
| Characteristic | Serious | Normal |
|---|---|---|
| N = 136 (%) | N = 295 (%) | |
| Drugs (top 10) | ||
| Cytarabine | 48 (42.5) | 65 (57.5) |
| Asparaginase | 11 (20.0) | 44 (80.0) |
| Methotrexate | 10 (20.4) | 39 (79.6) |
| Pegaspargase | 13 (35.1) | 24 (64.9) |
| Cyclophosphamide | 9 (30.0) | 21 (70.0) |
| Etoposide | 8 (36.4) | 14 (63.6) |
| Vincristine sulfate | 3 (17.6) | 14 (82.4) |
| Cisplatin | 4 (33.3) | 8 (66.7) |
| Daunorubicin | 5 (45.5) | 6 (54.5) |
| Doxorubicin | 6 (66.7) | 3 (33.3) |
| System organ class (top 10) | ||
| Gastrointestinal disorders | 19 (14.6) | 111 (85.4) |
| Blood and lymphatic system disorders | 73 (70.9) | 30 (29.1) |
| Skin and subcutaneous tissue disorders | 15 (17.6) | 70 (82.4) |
| General disorders and administration site conditions | 10 (21.3) | 37 (78.7) |
| Respiratory, thoracic, and mediastinal disorders | 5 (41.7) | 7 (58.3) |
| Nervous system disorders | 1 (10.0) | 9 (90.0) |
| Hepatobiliary disorders | 4 (40.0) | 6 (60.0) |
| Metabolism and nutrition disorders | 0 (0) | 7 (100) |
| Cardiac disorders | 4 (57.1) | 3 (42.9) |
| Immune system disorders | 1 (20.0) | 4 (80.0) |
| ADR (top 10) | ||
| Myelosuppression | 57 (85.1) | 10 (14.9) |
| Rash | 9 (15.0) | 51 (85.0) |
| Vomiting | 7 (13.7) | 44 (86.3) |
| Fever | 9 (24.3) | 28 (75.7) |
| Nausea | 3 (11.5) | 23 (88.5) |
| Gastrointestinal reaction | 2 (10.0) | 18 (90.0) |
| Fibrinogen decreased | 3 (25.0) | 9 (75.0) |
| Leukocyte count decreased | 6 (60.0) | 4 (40.0) |
| Dyspnea | 4 (44.4) | 5 (55.6) |
| Hepatic failure | 4 (44.4) | 5 (55.6) |